PMID: 9416813Jan 7, 1998Paper

Long term effect of intravenous immunoglobulins and oral cyclophosphamide in multifocal motor neuropathy

Journal of Neurology, Neurosurgery, and Psychiatry
N MeucciEduardo Nobile-Orazio

Abstract

To report the long term effect of the combined treatment with high dose intravenous immunoglobulins (i.v.Ig) and oral cyclophosphamide (CTX) in patients with multifocal motor neuropathy, and to determine whether the association of oral CTX in these patients may help to delay and, possibly, suspend i.v.Ig infusions. Six patients with multifocal motor neuropathy responding to an initial course of i.v.Ig (0.4 g/kg/day for five consecutive days) were followed up for 37 to 61 (mean 47) months. All patients were subsequently treated with periodic i.v.Ig infusions (0.4 g/kg/day for two days at clinical worsening) and oral CTX (1-3 mg/kg/day). Improvement was assessed using the Rankin disability scale, a functional impairment scale for upper and lower limbs, and the MRC rating scale on the 20 most affected muscles. Electrophysiological and antiglycolipid antibody studies were performed before treatment, then yearly during follow up. All patients improved during treatment and, by the end of follow up or before worsening after therapy suspension, the median Rankin (P=0.0335) and upper (P=0.0015) and lower limb (P=0.0301) impairment scores and the mean MRC (P=0.0561) score were improved. By that time the number of nerves with partial moto...Continue Reading

References

Sep 1, 1991·Annals of Neurology·E L FeldmanA Pestronk
Nov 1, 1990·Neurology·E Nobile-OrazioG Scarlato
Jul 1, 1988·Annals of Neurology·A PestronkR N Adams
Jul 1, 1995·Journal of Neurology, Neurosurgery, and Psychiatry·P BoucheG Said
Sep 1, 1995·Journal of Neurology, Neurosurgery, and Psychiatry·L H Van den BergJ H Wokke
Feb 1, 1994·Muscle & Nerve·V ChaudhryJ W Griffin
Mar 1, 1993·Annals of Neurology·V ChaudhryJ W Griffin
Jun 1, 1996·Journal of Neurology, Neurosurgery, and Psychiatry·E Nobile-Orazio
May 1, 1995·Annals of Neurology·A J Kornberg, A Pestronk

❮ Previous
Next ❯

Citations

Aug 6, 2008·Der Nervenarzt·S Cursiefen, M Mäurer
Apr 19, 2005·Journal of Neurology·Eduardo Nobile-Orazio
Jun 17, 2005·Journal of Neurology·Eduardo Nobile-Orazio, Fabrizia Terenghi
Mar 22, 2013·Drugs·Eduardo Nobile-Orazio, Francesca Gallia
Nov 21, 2008·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Andreas J SteckSusanne Renaud
Mar 10, 2001·Transfusion·A RizkR Weinstein
Aug 2, 2006·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·UNKNOWN European Federation of Neurological SocietiesP A van Doorn
Aug 19, 2005·Journal of Neurology, Neurosurgery, and Psychiatry·A GhoshM Donaghy
Jul 10, 2003·Lancet Neurology·Jeyaraj D Pandian, Pooja Khosla
Feb 9, 2011·Expert Opinion on Biological Therapy·Filip Eftimov, Ivo N Van Schaik
Jul 24, 2001·Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders : Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases·E Nobile-OrazioN Meucci
Nov 26, 2015·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Jean-Marc LégerCristina Muntean
Jun 27, 2015·Journal of the Peripheral Nervous System : JPNS·Mariëlle H J PruppersUNKNOWN PeriNomS study group
Sep 4, 2015·Journal of the Peripheral Nervous System : JPNS·Els K VanhoutteUNKNOWN PeriNomS Study Group
May 28, 2014·Journal of the Peripheral Nervous System : JPNS·Antonios KerasnoudisMin-Suk Yoon
Dec 13, 2002·Brain : a Journal of Neurology·J T H Van AsseldonkH Franssen
May 6, 2015·Therapeutic Advances in Neurological Disorders·Jean-Marc LégerRuxandra Iancu Ferfoglia
Aug 21, 2003·Muscle & Nerve·Peter D Donofrio
Mar 17, 2005·Muscle & Nerve·Eduardo Nobile-OrazioAlberto Priori
Jun 7, 2005·Expert Opinion on Pharmacotherapy·Jean-Marc Léger
Nov 3, 2006·Expert Review of Neurotherapeutics·Yee-Cheun Chan, Einar Wilder-Smith
Sep 13, 2019·Journal of Neurology, Neurosurgery, and Psychiatry·Wei Zhen YehBruce V Taylor
Dec 16, 1998·Current Opinion in Neurology·H P HartungJ D Pollard
May 23, 2002·Clinical Neuropharmacology·Andrew J Gordon, Matthew N Meriggioli
Sep 5, 2006·Physiological Measurement·S M López-SilvaL Herrera
Apr 23, 2005·The Cochrane Database of Systematic Reviews·I N van SchaikM Vermeulen
Mar 5, 2015·The Cochrane Database of Systematic Reviews·T UmapathiJean-Marc Léger
Jul 16, 2009·Expert Opinion on Pharmacotherapy·Laurent Magy, Jean-Michel Vallat
Jan 17, 2021·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·Chiara BrianiEduardo Nobile-Orazio

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.